Key result
The -866G>A polymorphism in UCP-2 was not associated with stroke recurrence (p=0.57), but the A allele was significantly associated with clopidogrel resistance (p<0.0001).
Why the study?
Does the -866G>A polymorphism of UCP-2 affect platelet reactivity and prognosis in patients with type 2 diabetes and ischemic stroke?
Population
405 Chinese patients with type 2 diabetes and ischemic stroke
Comparison
-866G>A polymorphism of mitochondrial uncoupling… vs GG genotype of UCP-2
Design
Case-control
Follow-up
4 years
Authors
Loading...
UCP-2 -866G>A was associated with clopidogrel resistance but not recurrence; leaves open clinical utility pending validation.
Case-Control (n=405)
Does the -866G>A polymorphism of UCP-2 affect platelet reactivity and prognosis in patients with type 2 diabetes and ischemic stroke?
p-value: p=0.57
The UCP-2 -866G>A polymorphism is associated with clopidogrel resistance but not with recurrent stroke in Chinese patients with type 2 diabetes and ischemic stroke.
Chai et al. (2013) conducted a case-control in Type 2 diabetes and ischemic stroke (n=405). -866G>A polymorphism in UCP-2 vs. GG genotype was evaluated on Composite of stroke and TIA (p=0.57). The -866G>A polymorphism in UCP-2 was not associated with stroke recurrence (p=0.57), but the A allele was significantly associated with clopidogrel resistance (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: